Abstract 684TiP
Background
Enhancer of zeste homolog 2 (EZH2) and its close homolog EZH1 are the enzymatic core subunits of polycomb repressive complex 2 (PRC2). EZH1/2 repress the transcription of target genes by triggering tri-methylation of the lysine 27 residue of histone H3 (H3K27me3). H3K27me3 plays a critical role in cancer progression and is associated with poor prognosis. EZH2 gain-of-function (GOF) mutations or overexpression lead to hyper tri-methylation of H3K27 when loss-of-function mutation of major components of regulatory protein complexes promote cancer pathogenesis by losing its ability to oppose PRC2. Given that EZH1 compensates the activity of EZH2 in EZH2-depleted cells, dual inhibition of EZH1/2 is expected to have a greater anti-tumor activity through suppressing PRC2 function. In preclinical studies, HM97662, a novel EZH1/2 dual inhibitor have demonstrated simultaneous inhibition of the methyltransferase activity of wild-type EZH1/2 as well as GOF mutant EZH2. Given the promising preclinical results, first-in-human phase I study of HM97662 was designed.
Trial design
This is a phase I, open-label, multicenter study of HM97662 as a single agent in patients with advanced or metastatic solid tumors who have failed or are intolerant to standard therapy. Dose escalation part is planned with a 3+3 design to establish the maximum tolerated dose or recommended dose for the randomized dose ranging part. The starting dose is 50 mg once daily (QD) and may proceed to subsequent cohorts increased by 50 mg from the preceding cohort until the maximum dose of 350 mg QD. Randomized dose ranging part is mainly designed with the purpose of dose optimization by evaluating the safety and preliminary efficacy of HM97662 in patients with genomic alterations for more than one feasible doses selected from the dose escalation part. Dose expansion part is designed to assess and confirm the efficacy, safety, pharmacokinetics, and pharmacodynamics of HM97662 with specific target disease determined by available preclinical study results and clinical outcomes. The final analysis will be performed once or separately for each part based on study progression.
Clinical trial identification
NCT05598151.
Editorial acknowledgement
Legal entity responsible for the study
Hanmi Pharmaceutical Co. Ltd.
Funding
Hanmi Pharmaceutical Co. Ltd.
Disclosure
B. Keam: Financial Interests, Personal, Invited Speaker: Merck, Lilly, MSD, LG Chem; Financial Interests, Personal, Advisory Board: Handok, TrialInformatics, ImmunOncia, NeoImmunetech, Beigen; Financial Interests, Personal, Coordinating PI: MSD Oncology, AstraZeneca, Ono Pharmaceutical, Bayer. V. Ganju: Financial Interests, Personal, Other, Honoraria: Roche/Genentech, AstraZeneca. V. Kwatra: Financial Interests, Personal, Advisory Board: Roche. A. Body: Financial Interests, Institutional, Local PI: BeiGene, DayOne, Innovent, Gilead, Hanmi Pharmaceutical, Stingray Therapeutics, Vivace Therapeutics; Financial Interests, Institutional, Research Grant: Cancer Australia (Australian Government). P.D. Rhee, S. Jung, J. Yoon, E. Baek, Y.S. Noh: Financial Interests, Personal, Full or part-time Employment: Hanmi Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
661P - Safety and activity of CY-101 in patients with advanced solid tumors: The phase I/IIa CICILIA trial
Presenter: Barend Sikkema
Session: Poster session 01
662P - A phase I study evaluating IMM2520 (CD47/PD-L1 bispecific molecule) in pts with advanced solid tumor
Presenter: Yuping Sun
Session: Poster session 01
663P - First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumors
Presenter: Muhammad Khattak
Session: Poster session 01
664P - Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)
Presenter: Maria Julia Lostes Bardaji
Session: Poster session 01
665P - Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Thomas Marron
Session: Poster session 01
Resources:
Abstract
666P - Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients
Presenter: Sarah Blagden
Session: Poster session 01
667P - Phase I study to assess biodistribution of CB307, a trispecific Humabody targeting CD137, prostate-specific membrane antigen, and human serum albumin with 89Zr-CB307 PET
Presenter: Daan Geert Knapen
Session: Poster session 01
668P - First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable disease
Presenter: Thomas Marron
Session: Poster session 01
669P - CBX-12-101: Final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors
Presenter: Patricia Lorusso
Session: Poster session 01
670P - Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data
Presenter: Martin Wermke
Session: Poster session 01